Is Pro-Dex, Inc. (NASDAQ:PDEX) a buy in 2026?
Hold. Pro-Dex, Inc. is a wait-and-watch at today's price, not a fresh buy.
A genuinely excellent little machine shop for surgical robots, priced like the good news has already shown up.
Where PDEX is headed
Pro-Dex is one of the strangest good businesses in med-tech. A ~$70m revenue contract manufacturer of powered surgical drivers, sitting in Irvine, run lean, throwing off 17% operating margins and a 32% return on equity, with a market cap that has quadrupled off the 2024 lows. It exists because the big orthopedic names (think Stryker, DePuy, Medtronic's spine business, and the wave of robotic-surgery entrants) do not want to build torque-limiting autoclavable drivers themselves. Pro-Dex does, better than almost anyone, and locks in multi-year programs where the driver is spec'd into an FDA-cleared kit. Once you're in, you're in for the life of the procedure code.
Read the full Compass Direction on PDEX
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $62.21).
See the full PDEX analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Pro-Dex, Inc. (NASDAQ:PDEX) a buy in 2026?
Hold. Pro-Dex, Inc. is a wait-and-watch at today's price, not a fresh buy. A genuinely excellent little machine shop for surgical robots, priced like the good news has already shown up.
What is PDEX's Compass Score?
Pro-Dex, Inc. scores 72/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for PDEX?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the PDEX page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.